275 related articles for article (PubMed ID: 34622365)
1. Histamine receptors in heart failure.
Levick SP
Heart Fail Rev; 2022 Jul; 27(4):1355-1372. PubMed ID: 34622365
[TBL] [Abstract][Full Text] [Related]
2. Aggravated myocardial infarction-induced cardiac remodeling and heart failure in histamine-deficient mice.
Chen J; Hong T; Ding S; Deng L; Abudupataer M; Zhang W; Tong M; Jia J; Gong H; Zou Y; Wang TC; Ge J; Yang X
Sci Rep; 2017 Mar; 7():44007. PubMed ID: 28272448
[TBL] [Abstract][Full Text] [Related]
3. The role of neuropeptides in adverse myocardial remodeling and heart failure.
Widiapradja A; Chunduri P; Levick SP
Cell Mol Life Sci; 2017 Jun; 74(11):2019-2038. PubMed ID: 28097372
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the Cardiovascular System by Histamine.
Hattori Y; Hattori K; Matsuda N
Handb Exp Pharmacol; 2017; 241():239-258. PubMed ID: 27838850
[TBL] [Abstract][Full Text] [Related]
5. Novel Insights into the Crosstalk between Mineralocorticoid Receptor and G Protein-Coupled Receptors in Heart Adverse Remodeling and Disease.
Parker BM; Wertz SL; Pollard CM; Desimine VL; Maning J; McCrink KA; Lymperopoulos A
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486399
[TBL] [Abstract][Full Text] [Related]
6. A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
Takahama H; Asanuma H; Sanada S; Fujita M; Sasaki H; Wakeno M; Kim J; Asakura M; Takashima S; Minamino T; Komamura K; Sugimachi M; Kitakaze M
Basic Res Cardiol; 2010 Nov; 105(6):787-94. PubMed ID: 20852875
[TBL] [Abstract][Full Text] [Related]
7. GRK2 inhibition in heart failure: something old, something new.
Lymperopoulos A; Rengo G; Koch WJ
Curr Pharm Des; 2012; 18(2):186-91. PubMed ID: 22229578
[TBL] [Abstract][Full Text] [Related]
8. The histamine H4 receptor in autoimmune disease.
Zhang M; Venable JD; Thurmond RL
Expert Opin Investig Drugs; 2006 Nov; 15(11):1443-52. PubMed ID: 17040202
[TBL] [Abstract][Full Text] [Related]
9. Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system.
Reid AC; Brazin JA; Morrey C; Silver RB; Levi R
Curr Pharm Des; 2011 Nov; 17(34):3744-52. PubMed ID: 22103845
[TBL] [Abstract][Full Text] [Related]
10. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension.
Chunduri P; Patel SA; Levick SP
Adv Pharmacol; 2022; 94():183-211. PubMed ID: 35659372
[TBL] [Abstract][Full Text] [Related]
11. Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure.
Ruffolo RR; Kopia GA
Am J Med; 1986 Feb; 80(2B):67-72. PubMed ID: 2868661
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of histamine receptor subtypes.
Arrang JM
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):275-81. PubMed ID: 7920174
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure.
Hanna A; Frangogiannis NG
Cardiovasc Drugs Ther; 2020 Dec; 34(6):849-863. PubMed ID: 32902739
[TBL] [Abstract][Full Text] [Related]
14. Association of histamine with hypertension-induced cardiac remodeling and reduction of hypertrophy with the histamine-2-receptor antagonist famotidine compared with the beta-blocker metoprolol.
Potnuri AG; Allakonda L; Appavoo A; Saheera S; Nair RR
Hypertens Res; 2018 Dec; 41(12):1023-1035. PubMed ID: 30310171
[TBL] [Abstract][Full Text] [Related]
15. β-Arrestin2 Improves Post-Myocardial Infarction Heart Failure via Sarco(endo)plasmic Reticulum Ca
McCrink KA; Maning J; Vu A; Jafferjee M; Marrero C; Brill A; Bathgate-Siryk A; Dabul S; Koch WJ; Lymperopoulos A
Hypertension; 2017 Nov; 70(5):972-981. PubMed ID: 28874462
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure.
Rengo G; Cannavo A; Liccardo D; Zincarelli C; de Lucia C; Pagano G; Komici K; Parisi V; Scala O; Agresta A; Rapacciuolo A; Perrone Filardi P; Ferrara N; Koch WJ; Trimarco B; Femminella GD; Leosco D
Circ Heart Fail; 2013 Nov; 6(6):1259-67. PubMed ID: 24029661
[TBL] [Abstract][Full Text] [Related]
17. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure.
Iwata M; Cowling RT; Yeo SJ; Greenberg B
J Mol Cell Cardiol; 2011 Oct; 51(4):542-7. PubMed ID: 21147120
[TBL] [Abstract][Full Text] [Related]
18. Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: inhibition by histamine H3 and H4 receptor activation.
Chan NY; Robador PA; Levi R
J Pharmacol Exp Ther; 2012 Dec; 343(3):568-77. PubMed ID: 22923736
[TBL] [Abstract][Full Text] [Related]
19. An "I" on cardiac hypertrophic remodelling: imidazoline receptors and heart disease.
Mukaddam-Daher S
Can J Cardiol; 2012; 28(5):590-8. PubMed ID: 22483786
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
